article_snippet: British researchers involve taking T-cells, which fight infection, and giving British researchers the ability to recognise a special tag on the surface of cancer cells, called the WT1 protein.
article_snippet: whose cells tend to have WT1 on whose cells surfaces.
article_snippet: The treatments do this by giving T-cells the ability to detect a key marker called WT1 .
article_snippet: WT1 is a protein found on the surface of the cells of many types of cancer .
article_snippet: The patient receives stem cells and T-cells straight away but the T-cells are sensitised to WT1 in the lab by exposing the T-cells to fragments of the protein.
article_snippet: In the British study, led by Dr Emma Morris – a haematologist at University College London and the Royal Free Hospital, T-cells from up to 20 patients with acute myeloid leukaemia or chronic myeloid leukaemia are to be extracted, inserted with DNA so the Royal Free Hospital, T-cells from up to 20 patients with acute myeloid leukaemia or chronic myeloid leukaemia recognise WT1, and then put back again.
article_snippet: We have genetically engineered patients’ immune cells so patients develop receptors for the WT1 protein, making patients much better at recognising leukaemia cells.
article_snippet: These then provide the blueprint to build the WT1 receptor.
article_snippet: Next, her brother Walter’s bone marrow were exposed to WT1 protein.